The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treat Rheumatoid Arthritis to Target

Treat Rheumatoid Arthritis to Target

April 13, 2011 • By Elana J. Bernstein, MD; Allan Gibofsky, MD, JD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Treat Rheumatoid Arthritis to Target
With a target in focus, it’s time to start goal-directed treatment of rheumatoid arthritis.

The goal of “treating to a target” is not a new concept in clinical medicine. Indeed, in many specialties, goal-directed treating to target is already the standard. For example, the goal of reducing low-density lipoprotein is widely accepted and followed by cardiologists and primary care physicians (PCPs), as determined by the number of coronary artery disease risk factors present in each patient. The Joint National Commission (JNC) 7 blood pressure guidelines have also been widely adopted by the medical community. Physicians have come to accept that blood pressure must not exceed 140/90 mmHg in “normal” patients, and that blood pressures less than 130/80 mmHg must be targeted in patients with diabetes or chronic kidney disease. Finally, endocrinologists and PCPs alike recognize the importance of achieving a hemoglobin A1C level as close to 6.0 mg/dl as possible, and use this value as an indicator of the success of their therapeutic strategy in achieving “tight” control of the patient’s diabetes in the outpatient setting.

You Might Also Like
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Treat to Target: Rheumatoid Arthritis in Pregnant Patients
  • Patient’s Journey with Rheumatoid Arthritis Redefines ‘Treat to Target’
Explore This Issue
April 2011

At the same time, recent studies of patients with diabetes have shown that pushing for hemoglobin A1C levels less than 6.5 mg/dl in the elderly population may also lead to increased morbidity and mortality. The lesson from these studies is that “treating to target” is beneficial not just to avoid undertreating, but to avoid overtreating as well. It is difficult, however, to define the boundaries of overtreating and undertreating without first setting a target.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

TABLE 1: Recommendations from the International Treat to Target Initiative

Overarching principles:

  1. The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist.
  2. The primary goal of treating the patient with rheumatoid arthritis is to maximize long-term ,health-related quality of life through control of symptoms, prevention of structural damage, normalization of function and social participation.
  3. Abrogation of inflammation is the most important way to achieve these goals.
  4. Treatment to target by measuring disease activity and adjusting therapy accordingly optimizes outcomes in rheumatoid arthritis.

Ten recommendations on treating rheumatoid arthritis to target based on both evidence and expert opinion:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. The primary target for treatment of rheumatoid arthritis should be a state of clinical remission.
  2. Clinical remission is defined as the absence of signs and symptoms of significant inflammatory disease activity.
  3. While remission should be a clear target, based on available evidence low disease activity may be an acceptable alternative therapeutic goal, particularly in established long-standing disease.
  4. Until the desired treatment target is reached, drug therapy should be adjusted at least every 3 months.
  5. Measures of disease activity must be obtained and documented regularly, as frequently as monthly for patients with high/moderate disease activity or less frequently (such as every 3–6 months) for patients in sustained low disease activity or remission.
  6. The use of validated composite measures of disease activity, which include joint assessments, is needed in routine clinical practice to guide treatment decisions.
  7. Structural changes and functional impairment should be considered when making clinical decisions, in addition to assessing composite measures of disease activity.
  8. The desired treatment target should be maintained throughout the remaining course of the disease.
  9. The choice of the (composite) measure of disease activity and the level of the target value may be influenced by consideration of co-morbidities, patient factors, and drug-related risks.
  10. The patient has to be appropriately informed about the treatment target and the strategy planned to reach this target under the supervision of the rheumatologist.

Source: Ann Rheum Dis. 2010;69:631-637.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: disease management, Research, Rheumatoid Arthritis (RA), Treat-to-TargetIssue: April 2011

You Might Also Like:
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Treat to Target: Rheumatoid Arthritis in Pregnant Patients
  • Patient’s Journey with Rheumatoid Arthritis Redefines ‘Treat to Target’
  • MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)